Search

Your search keyword '"zafirlukast"' showing total 14 results
Start Over Descriptor "zafirlukast" Publication Type News
14 results on '"zafirlukast"'

1. Findings in Kidney Cancer Reported from Goethe-University Frankfurt (Zafirlukast Induces Vhl- and Hif-2 Alpha-dependent Oxidative Cell Death In 786-o Clear Cell Renal Carcinoma Cells)

Subjects
Care and treatment, Kidney cancer -- Care and treatment, Olaparib, Cancer research, Biochemistry, Cell death, Carcinoma -- Care and treatment, Zafirlukast, Oncology, Experimental, Cancer -- Care and treatment -- Research
Abstract

2022 MAY 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Oncology - Kidney Cancer have been published. According to [...]

Published
2022

5. Reports from Goethe-University Frankfurt Provide New Insights into Leukocyte Biology (Quantitative Single-molecule Imaging of Tnfr1 Reveals Zafirlukast As Antagonist of Tnfr1 Clustering and Tnf Alpha-induced Nf-& X138;b Signaling)

Subjects
Apoptosis, Tumor necrosis factor, Zafirlukast, Biochemistry, Cell death, Autoimmune diseases, Editors, Diseases
Abstract

2020 JUN 2 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Data detailed on Biology - Leukocyte Biology have been presented. According to news reporting [...]

Published
2020

7. Invion and Hovione Sign Joint Development and Licensing Agreement for Inhaled Zafirlukast

Subjects
Asthma, Pharmaceutical industry -- Licensing agreements, Zafirlukast, Company licensing agreement, Business, News, opinion and commentary
Abstract

- Hovione Scientia Limited committing to a cost-profit sharing co-development and licensing partnership with Invion to develop and manufacture inhaled INV104 using Hovione's proprietary inhaler - Invion to oversee clinical [...]

Published
2015

8. INVION AND HOVIONE SIGN LICENSING AGREEMENT

Subjects
Licensing agreements, Company licensing agreement, Asthma, Zafirlukast
Abstract

Australian drug development company Invion Limited, has secured a commitment from Hovione Scientia Limited, an international pharmaceutical company expert in inhalation development and manufacturing, to progress development of inhaled INV104 [...]

Published
2015

10. Dr. Reddy's Laboratories launches Zafirlukast tablets in US

Subjects
United States. Food and Drug Administration, AstraZeneca PLC, Generic drugs, Zafirlukast, Pharmaceutical industry, General interest, News, opinion and commentary, Accolate (Medication)
Abstract

Nov 22, 2010 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Saturday the launch of its Zafirlukast tablets (10mg and 20mg) in the US market, [...]

Published
2010

11. Dr Reddy's announces the launch of Zafirlukast tablets

Subjects
Generic drugs, Zafirlukast, Business, Chemicals, plastics and rubber industries, Accolate (Medication)
Abstract

Dr Reddy's Laboratories has launched Zafirlukast tablets, a bioequivalent generic version of Accolate in the US market. On 15 Nov 2010 the US District Court of New Jersey granted Dr [...]

Published
2010

12. Dr. Reddy's announces the Launch of Zafirlukast Tablets

Subjects
United States. Food and Drug Administration, Generic drugs, Zafirlukast, Business, Business, international, Accolate (Medication)
Abstract

HYDERABAD, India -- Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zafirlukast tablets (10 mg and 20 mg), a bioequivalent generic version of Accolate[R] in the US [...]

Published
2010

13. New and generic drug approvals: Zafirlukast Oral Tablet, Dr Reddy's Labs

Subjects
Generic drugs, Zafirlukast, Drug approval, Pharmaceutical industry, Business, Chemicals, plastics and rubber industries
Abstract

On 1 Jun 2010, the US Food and Drug Administration announced the tentative approval of ANDA 090372 for Zafirlukast Oral Tablet. The product contains zafirlukast at 10mg or 20mg and [...]

Published
2010

14. Dr. Reddya[euro](tm)s Laboratories launches Zafirlukast tablets in US

Subjects
United States. Food and Drug Administration, AstraZeneca PLC, Generic drugs, Zafirlukast, Pharmaceutical industry, Business, Accolate (Medication)
Abstract

M2 EQUITYBITES-November 22, 2010-Dr. Reddyâ[euro](tm)s Laboratories launches Zafirlukast tablets in US(C)2010 M2 COMMUNICATIONS http://www.m2.com Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Saturday the launch of its Zafirlukast tablets (10mg [...]

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results